Avatrombopag for persistent and chronic immune thrombocytopenia in children: A post hoc analysis of clinical characteristics of response from a phase 3b clinical trial

Gynecologic Cancer

Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): 10-year clinical outcomes and post-hoc analysis by molecular classification from a randomised phase 3 trial

★ 3 Recommended and commented by Dr Andreas Müller, Faculty Member

★ 1 Recommended by Prof. Dr Beat Thürlimann, Faculty Member

Lancet Oncol

Post CCB, de Boer SM, Powell ME, Mileshkin L, Katsaros D, Bessette P, Leary A, Ottevanger PB, McCormack M, Khaw P, D'Amico R, Fyles A, Chargari C, Kitchener HC, Do V, Lissoni A, Provencher D, Genestie C, Nijman HW, Whitmarsh K, Jürgenliemk-Schulz IM, Feeney A, Lutgens LCHW, Bouma J, Leon-Castillo A, Nout RA, Putter H, Bosse T, Creutzberg CL

doi: 10.1016/S1470-2045(25)00379-1

Gastrointestinal Cancer

Predictive Role of Circulating Tumor DNA in Stage III Colon Cancer Treated With Celecoxib: A Post Hoc Analysis of the CALGB (Alliance)/SWOG 80702 Phase 3 Randomized Clinical Trial

JAMA Oncol

Zhang GQ, Meyerhardt JA, Shi Q, Twombly T, Pederson L, Ma C, Väyrynen JP, Zhao M, Takashima Y, Shergill A, Kumar P, Couture F, Kuebler P, Krishnamurthi S, Tan B, O'Reilly EM, Giannakis M, Ogino S, Jurdi A, Sharma S, Aleshin A, Shields AF, Nowak JA

doi: 10.1001/jamaoncol.2025.5144

Lung, Respiratory and Thoracic Cancer

Validation of the lung immune prognostic index in extensive-stage small cell lung cancer: Post hoc analysis of the caspian and IMpower133 phase 3 trials

Eur J Cancer

Auclin E, Roulleaux Dugage M, Gorría T, Laguna JC, Anguita D, Montes A, Rota M, Ferriol-Galmes M, Vauchier C, Lavaud P, Besse B, Mezquita L

doi: 10.1016/j.ejca.2026.116955

Further Publications

Predictors of clinically relevant bleeding during extended anticoagulation for cancer-associated venous thromboembolism (API-CAT): a post-hoc analysis of a randomised, non-inferiority trial

Lancet Haematol

Mahé I, Chapelle C, Girard P, Carrier M, Palomares LJ, Samama CM, Helfer H, Gerotziafas G, Laporte S, Vicaut E, Mismetti P, API-CAT Study Group, API-CAT Investigators

doi: 10.1016/S2352-3026(25)00291-1

Gastrointestinal Cancer

Durvalumab Plus Chemotherapy for Advanced Biliary Tract Cancer: A Post Hoc Analysis of the TOPAZ-1 Randomized Clinical Trial

JAMA Oncol

Oh DY, He AR, Qin S, Chen LT, Okusaka T, Griffin R, Wang J, Xynos I, Vogel A, Valle JW

doi: 10.1001/jamaoncol.2026.2204

RECOMMENDED

Breast Cancer

Metronomic capecitabine as extended adjuvant chemotherapy for early triple-negative breast cancer (SYSUCC-001): updated 10-year outcomes and post-hoc exploratory biomarker analysis from a randomised, phase 3 trial

★ 1 Recommended by Prof. Dr Beat Thürlimann, Faculty Member

Lancet Oncol

Yuan J, Bi XW, Hua X, Huang H, Cai L, Zhao L, Chen QJ, Chen XX, Wang XL, Lin Y, Zhang AQ, Zhong YY, Xu F, Huang JJ, An X, Shi YX, Wang X, Wang SS, Xue C, Yuan ZY

doi: 10.1016/S1470-2045(25)00545-5

Genitourinary Cancer

On-treatment serum prostate-specific antigen and overall survival in prostate cancer (STAMPEDE platform protocol): a post-hoc analysis of data from five phase 3 trials

Lancet Oncol

Kayani M, Murphy L, Dutey-Magni P, Howlett S, Sachdeva A, Padden-Modi M, Abdel-Aty H, Brown LC, Amos CL, Chan K, Gilbert DC, Langley RE, Brown M, Sydes MR, Parker CC, STAMPEDE Collaborators, Cross W, Malik Z, Varughese M, Turco F, Millman R, Matheson D, Gillessen S, Clarke NW, Parmar MKB, James ND, Attard G

doi: 10.1016/S1470-2045(26)00066-5

Leukemia

Children with chronic phase chronic myeloid leukemia: characteristics and outcomes from the International Registry of Childhood CML

Haematologica

Millot F, De Keizer J, Metzler M, Kalwak K, Günes AM, De Moerloose B, Luesink M, Honrubia AM, Sedlacek P, Yajima J, Ampatzidou M, Dworzak M, Lausen B, Borisevich M, Li CK, Kolenova A, Jakovljevic G, Farah R, Durocher L, Baruchel A, Suttorp M

doi: 10.3324/haematol.2025.288283

Further Publications

Clinical Predictors of Response in Chronic Graft-Versus-Host Disease: Results From the "Predicting the Quality of Response to Specific Treatments (PQRST)" Trial

Am J Hematol

Hamilton BK, Onstad L, Carpenter PA, Pidala J, Chen G, Cutler C, El Jurdi N, Farhadfar N, Juckett M, Kitko CL, Lee CJ, Lee SJ

doi: 10.1002/ajh.70427

Related content

Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): 10-year clinical outcomes and post-hoc analysis by molecular classification from a randomised phase 3 trial

Predictive Role of Circulating Tumor DNA in Stage III Colon Cancer Treated With Celecoxib: A Post Hoc Analysis of the CALGB (Alliance)/SWOG 80702 Phase 3 Randomized Clinical Trial

Validation of the lung immune prognostic index in extensive-stage small cell lung cancer: Post hoc analysis of the caspian and IMpower133 phase 3 trials

Predictors of clinically relevant bleeding during extended anticoagulation for cancer-associated venous thromboembolism (API-CAT): a post-hoc analysis of a randomised, non-inferiority trial

Durvalumab Plus Chemotherapy for Advanced Biliary Tract Cancer: A Post Hoc Analysis of the TOPAZ-1 Randomized Clinical Trial

Metronomic capecitabine as extended adjuvant chemotherapy for early triple-negative breast cancer (SYSUCC-001): updated 10-year outcomes and post-hoc exploratory biomarker analysis from a randomised, phase 3 trial

On-treatment serum prostate-specific antigen and overall survival in prostate cancer (STAMPEDE platform protocol): a post-hoc analysis of data from five phase 3 trials

Children with chronic phase chronic myeloid leukemia: characteristics and outcomes from the International Registry of Childhood CML

Clinical Predictors of Response in Chronic Graft-Versus-Host Disease: Results From the "Predicting the Quality of Response to Specific Treatments (PQRST)" Trial